98%
921
2 minutes
20
Background: There has been limited success using left bundle branch area pacing (LBBAP) in patients with severe interventricular septal hypertrophy (IVSH).
Objective: This study assesses the feasibility, safety, and outcome of LBBAP in patients with severe IVSH.
Methods: 19 adult patients with severe IVSH who underwent LBBAP were enrolled. Baseline patient characteristics, procedural data, and postprocedural results were collected. The feasibility of LBBAP in patients with severe IVSH using the lumenless leads (LLL) and stylet-driven leads (SDL) were analyzed.
Results: 19 IVSH and 529 normal septal thickness (NST) patients underwent LBBAP. Implant success was achieved in 497 patients with NST (93.9%) and 14 patients with severe IVSH (73.6%). Among the 19 patients with severe IVSH, 7 patients underwent attempted LBBAP using LLL, with successful outcomes in 4 (57.1%). The remaining 12 patients underwent LBBAP with SDL, of which 10 were successful (83.3%). Mean septal thickness (20 ± 1.9 vs 21 ± 2.2), paced QRS duration (123 ± 17 vs 121 ± 9), and left ventricular activation time (LVAT) (75 ± 6 vs 74 ± 9) were comparable in the LLL and SDL groups. The lead thresholds (0.8 ± 0.3) remained stable over the mean follow-up duration of 36 ± 28.67 months without any lead-related complications.
Conclusion: LBBAP in patients with severe IVSH is safe and feasible. Although the overall success rates in this subgroup were lower (73.6%) compared with patients with NST, this was not significantly different with the use of SDL (83.3%) ( = .15).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147595 | PMC |
http://dx.doi.org/10.1016/j.hroo.2025.02.018 | DOI Listing |
Br J Haematol
September 2025
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Refractory cytomegalovirus (CMV) infection is a severe complication following umbilical cord blood transplantation (UCBT). Antiviral agents, the standard first-line therapy, are limited by toxicity and resistance without robust T-cell immunity. We evaluated third-party donor (TPD)-derived CMV-specific T cells (CMVSTs) as a treatment option.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
Wounds
August 2025
Department of Nursing, Federal University of Ceará, Ceará, Brazil.
Background: Diabetic foot ulcers (DFUs) are a major clinical challenge, particularly among patients with refractory ulcers, that often lead to severe complications such as infection, amputation, and high mortality. Innovations supported by strong clinical evidence have the potential to improve healing outcomes, enhance quality of life, and reduce the economic burden on individuals and health care systems.
Objective: To describe the design of the concurrent optical and magnetic stimulation (COMS) therapy Investigational Device Exemption (IDE) study for refractory DFUs (MAVERICKS) trial.
Br J Pharmacol
September 2025
Department of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Background And Purpose: Neuroinflammation is increasingly recognised to contribute to drug-resistant epilepsy. Activation of ATP-gated P2X7 receptors has emerged as an important upstream mechanism, and increased P2X7 receptor expression is present in the seizure focus in rodent models and patients. Pharmacological antagonists of P2X7 receptors attenuate seizures in rodents, but this has not been explored in human neural networks.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDF